An assessment of antiviral drugs for the management of infectious diseases in humans.
D000547:Amantadine / Q000627:therapeutic use; D000998:Antiviral Agents / Q000627:therapeutic use*; D001205:Ascorbic Acid / Q000627:therapeutic use; D004304:Dosage Forms; D004341:Drug Evaluation; D004660:Encephalitis / Q000188:drug therapy; D006505:Hepatitis / Q000188:drug therapy; D006561:Herpes Simplex / Q000188:drug therapy; D006562:Herpes Zoster / Q000188:drug therapy; D006801:Humans; D007065:Idoxuridine / Q000627:therapeutic use; D007251:Influenza, Human / Q000188:drug therapy; D007542:Inosine Pranobex / Q000627:therapeutic use; D007372:Interferons / Q000627:therapeutic use; D007978:Levamisole / Q000627:therapeutic use; D012299:Rimantadine / Q000627:therapeutic use; D013344:Subacute Sclerosing Panencephalitis / Q000188:drug therapy; D014271:Trifluridine / Q000627:therapeutic use; D014777:Virus Diseases / Q000188:drug therapy
D000998:Antiviral Agents; D004304:Dosage Forms; D012299:Rimantadine; D007978:Levamisole; D007372:Interferons; D000547:Amantadine; D007065:Idoxuridine; D001205:Ascorbic Acid; D014271:Trifluridine; D007542:Inosine Pranobex